Prognostic value of prior consolidation in acute myeloid leukemia patients undergoing hematopoietic cell transplantation in minimal residual disease-negative first complete remission.
作者信息
How Joan, Vij Kiran R, Ebadi Maryam, DeFor Todd E, Romee Rizwan, Dolan Michelle M, Ustun Celalettin, Weisdorf Daniel J, Linden Michael A, Rashidi Armin
机构信息
Department of Medicine, Washington University School of Medicine, St. Louis, Missouri.
Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri.
出版信息
Am J Hematol. 2018 Dec;93(12):E381-E383. doi: 10.1002/ajh.25262. Epub 2018 Oct 9.
Abstract
摘要
相似文献
1
Prognostic value of prior consolidation in acute myeloid leukemia patients undergoing hematopoietic cell transplantation in minimal residual disease-negative first complete remission.微小残留病阴性首次完全缓解的急性髓系白血病患者接受造血细胞移植时既往巩固治疗的预后价值
Am J Hematol. 2018 Dec;93(12):E381-E383. doi: 10.1002/ajh.25262. Epub 2018 Oct 9.
2
History of consolidation is prognostic in acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation in minimal residual disease-negative first complete remission.在微小残留病阴性的首次完全缓解期接受异基因造血细胞移植的急性髓系白血病患者中，巩固治疗史具有预后意义。
Am J Hematol. 2017 Oct;92(10):1032-1036. doi: 10.1002/ajh.24834. Epub 2017 Jul 29.
3
GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia.GIMEMA AML1310 试验：针对新诊断的急性髓系白血病的年轻成年人，采用风险适应、MRD 导向的治疗。
Blood. 2019 Sep 19;134(12):935-945. doi: 10.1182/blood.2018886960. Epub 2019 Aug 8.
4
Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation.诊断时WT1转录水平低预示着接受化疗或异基因造血干细胞移植的t(8;21)急性髓系白血病患者预后不良。
Chin J Cancer. 2016 May 19;35:46. doi: 10.1186/s40880-016-0110-6.
5
Consolidation chemotherapy prior to hematopoietic cell transplantation for adults with acute myeloid leukemia in first remission.首次缓解的成人急性髓系白血病患者造血细胞移植前的巩固化疗。
Best Pract Res Clin Haematol. 2016 Dec;29(4):365-371. doi: 10.1016/j.beha.2016.10.012. Epub 2016 Oct 19.
6
When should patients receive consolidation chemotherapy before allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission?对于首次完全缓解的急性髓系白血病患者，在进行异基因造血细胞移植之前何时应接受巩固化疗？
Curr Opin Hematol. 2018 Mar;25(2):75-80. doi: 10.1097/MOH.0000000000000410.
7
Impact of Consolidation Cycles Before Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission.在首次完全缓解时进行异基因造血细胞移植前巩固周期对急性髓系白血病的影响。
Clin Lymphoma Myeloma Leuk. 2018 Dec;18(12):e529-e535. doi: 10.1016/j.clml.2018.08.010. Epub 2018 Aug 29.
8
Outcomes of Intermediate Risk Karyotype Acute Myeloid Leukemia in First Remission Undergoing Autologous Stem Cell Transplantation Compared With Allogeneic Stem Cell Transplantation and Chemotherapy Consolidation: A Retrospective, Propensity-score Adjusted Analysis.自体干细胞移植与异基因干细胞移植及化疗巩固治疗相比，首次缓解的中危核型急性髓系白血病的疗效：一项回顾性、倾向评分调整分析
Clin Lymphoma Myeloma Leuk. 2018 Nov;18(11):e481-e491. doi: 10.1016/j.clml.2018.07.290. Epub 2018 Jul 17.
9
Impact of postremission consolidation chemotherapy on outcome after reduced-intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia in first complete remission: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.缓解后强化化疗对首次完全缓解的急性髓系白血病患者行低强度预处理异基因造血干细胞移植后结局的影响：来自欧洲血液和骨髓移植学会急性白血病工作组的报告。
Cancer. 2014 Mar 15;120(6):855-63. doi: 10.1002/cncr.28498. Epub 2013 Dec 10.
10
Prognostic relevance of remission and measurable residual disease status in AML patients prior to reduced intensity or non-myeloablative allogeneic stem cell transplantation.在减低强度或非清髓性异基因干细胞移植前，急性髓系白血病患者缓解和可测量残留病状态的预后相关性。
Blood Cancer J. 2021 Apr 29;11(4):80. doi: 10.1038/s41408-021-00471-x.
引用本文的文献
1
Intensive post-remission therapy does not decrease relapse after allotransplants for acute myeloid leukaemia in 1st remission and should not be given.强化缓解后治疗并不能降低首次缓解的急性髓系白血病患者异基因移植后的复发率，不应给予该治疗。
Leukemia. 2025 May;39(5):1053-1055. doi: 10.1038/s41375-025-02560-3. Epub 2025 Mar 12.
2
More than two courses of pre-transplant consolidation therapy benefits patients with acute myeloid leukemia in the first complete remission who underwent human leukocyte antigen-matched sibling allografts: a multicenter study.在接受人类白细胞抗原匹配的同胞异体移植后，处于首次完全缓解期的急性髓细胞白血病患者，接受两疗程以上的移植前巩固治疗有益：一项多中心研究。
Chin Med J (Engl). 2023 Aug 5;136(15):1855-1863. doi: 10.1097/CM9.0000000000002347.
3
[Effect of consolidation before allogeneic hematopoietic stem cell transplantation for non-favorable acute myeloid leukemia patients with first complete remisson and negative minimal residual disease].[巩固治疗对首次完全缓解且微小残留病阴性的非预后良好型急性髓系白血病患者异基因造血干细胞移植的影响]
Zhonghua Xue Ye Xue Za Zhi. 2020 Jan 14;41(1):16-22. doi: 10.3760/cma.j.issn.0253-2727.2020.01.004.
本文引用的文献
1
History of consolidation is prognostic in acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation in minimal residual disease-negative first complete remission.在微小残留病阴性的首次完全缓解期接受异基因造血细胞移植的急性髓系白血病患者中，巩固治疗史具有预后意义。
Am J Hematol. 2017 Oct;92(10):1032-1036. doi: 10.1002/ajh.24834. Epub 2017 Jul 29.
2
Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia.具有细胞遗传学和分子诊断特征的移植前微小残留病可改善急性髓系白血病的风险分层。
Haematologica. 2017 Jan;102(1):110-117. doi: 10.3324/haematol.2016.144253. Epub 2016 Aug 18.
3
Myeloablative, but not Reduced-Intensity, Conditioning Overcomes the Negative Effect of Flow-Cytometric Evidence of Leukemia in Acute Myeloid Leukemia.清髓性而非减低剂量预处理可克服急性髓系白血病中白血病流式细胞术证据的负面影响。
Biol Blood Marrow Transplant. 2016 Apr;22(4):669-675. doi: 10.1016/j.bbmt.2015.10.024. Epub 2015 Nov 10.
4
Marked Variability in Reported Minimal Residual Disease Lower Level of Detection of 4 Hematolymphoid Neoplasms: A Survey of Participants in the College of American Pathologists Flow Cytometry Proficiency Testing Program.4种血液淋巴系统肿瘤报告的微小残留病检测下限存在显著差异：美国病理学家学会流式细胞术能力验证计划参与者调查
Arch Pathol Lab Med. 2015 Oct;139(10):1276-80. doi: 10.5858/arpa.2014-0543-CP. Epub 2015 Feb 19.
5
Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation.比较接受清髓性或非清髓性异基因造血细胞移植的处于首次完全缓解期的 AML 患者微小残留病作为预后指标的差异。
Leukemia. 2015 Jan;29(1):137-44. doi: 10.1038/leu.2014.173. Epub 2014 Jun 3.
6
Achieving stringent CR is essential before reduced-intensity conditioning allogeneic hematopoietic cell transplantation in AML.在急性髓系白血病（AML）患者接受降低强度预处理的异基因造血细胞移植之前，实现严格的完全缓解（CR）至关重要。
Bone Marrow Transplant. 2013 Nov;48(11):1415-20. doi: 10.1038/bmt.2013.124. Epub 2013 Aug 12.
Zotero 插件